Actavia Life Sciences (Actavia Life Sciences) Change In Receivables : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Actavia Life Sciences Change In Receivables?

Actavia Life Sciences's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Actavia Life Sciences's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Actavia Life Sciences's change in receivables for the fiscal year that ended in Sep. 2023 was $0.00 Mil. It means Actavia Life Sciences's Accounts Receivable stayed the same from Sep. 2022 to Sep. 2023 .

Actavia Life Sciences's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Actavia Life Sciences's liquidation value for the three months ended in Mar. 2024 was $-2.23 Mil.

Actavia Life Sciences Change In Receivables Historical Data

The historical data trend for Actavia Life Sciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actavia Life Sciences Change In Receivables Chart

Actavia Life Sciences Annual Data

Trend

Jun14

Jun15

Jun16

Mar17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Change In Receivables

Get a 7-Day Free Trial

0.22

0.01

Actavia Life Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Actavia Life Sciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Actavia Life Sciences (OTCPK:RASP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Actavia Life Sciences's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Actavia Life Sciences's accounts receivable are only considered to be worth 75% of book value:

Actavia Life Sciences's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.001	-	2.23	+	0.75 * 0	+	0.5 * 0
=	-2.23

Actavia Life Sciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of Actavia Life Sciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Actavia Life Sciences (Actavia Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actavia Life Sciences Inc (OTCPK:RASP) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Avenue, Suite 2525, New York, NY, USA, 10170

Website

https://www.rasna.com

Rasna Therapeutics Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.

Actavia Life Sciences (Actavia Life Sciences) Headlines

No Headlines